Skip to main content
Fig. 1 | Journal of Inflammation

Fig. 1

From: A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030

Fig. 1

The effect of the 5-HT2B receptor antagonist AM1030 on SEA-induced cytokine responses in human PBMCs. Tacrolimus (Tac) and RS127445 were included as reference drugs. IFN-ɣ (a) and IL-2 (b) data obtained from two healthy blood donors were pooled by normalizing sample cytokine levels to untreated control and are presented as percent of SEA (10 pg/ml) control. The absolute levels of IFN-ɣ and IL-2 were 9.6-24 ng/ml and 1.4-1.5 ng/ml, respectively. IL-12 (c) and IL-5 (d) data were obtained from a single blood donor and are presented as absolute values. One sample t-test (a and b) and one-way ANOVA with Dunnett’s post test (c and d) were used for statistical analysis (*p < 0.05, **p < 0.01, ***p < 0.001). #At 1 nM, tacrolimus reduced IL-5 to background level. ¤At 30 μM, AM1030 reduced IL-5 to levels below detection

Back to article page